BridgeMD
New treatment option for Chronic Myeloid Leukemia
Official title Study of Olverembatinib (HQP1351) in Patients With CP-CML
ClinicalTrials.gov ID: NCT06423911
What this study is testing
What is olverembatinib?
olverembatinib is an investigational medicine, being studied as a potential treatment for chronic myeloid leukemia.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- A Global Multicenter, Open Label, Randomized, Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients with Chronic Phase Chronic Myeloid Leukemia (POLARIS-2)
- Phase 3: a large, late-stage study
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 99
You may be able to join if
- Patients eligible for inclusion in this study must meet all of the following criteria.
- Age ≥ 18 years old.
- Diagnosis of CML-CP
- Part A: Previously treated with at least two approved TKIs Part B: T315I mutation at screening.
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2.
You likely can't join if
- Patients eligible for this study must not meet any of the following criteria.
- For Part A only: T315I mutation at any time prior to starting study treatment.
- Active infection that requires systemic drug therapy
- Impairment of gastrointestinal (GI) function or GI disease that may significantly alter absorption of study drugs
- Previous treatment with or known / suspected hypersensitivity to olverembatinib or any of its excipients.
- Previous treatment with or known / suspected hypersensitivity to bosutinib or any of its excipients.
See the full eligibility criteria
- Patients eligible for inclusion in this study must meet all of the following criteria.
- Age ≥ 18 years old.
- Diagnosis of CML-CP
- Part A: Previously treated with at least two approved TKIs Part B: T315I mutation at screening.
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2.
- Written informed consent obtained prior to any screening procedures.
- Patients with adequate organ functions
- Patients eligible for this study must not meet any of the following criteria.
- For Part A only: T315I mutation at any time prior to starting study treatment.
- Active infection that requires systemic drug therapy
- Impairment of gastrointestinal (GI) function or GI disease that may significantly alter absorption of study drugs
- Previous treatment with or known / suspected hypersensitivity to olverembatinib or any of its excipients.
- Previous treatment with or known / suspected hypersensitivity to bosutinib or any of its excipients.
- Pregnant or nursing (lactating) women.
The study team makes the final eligibility decision.
Where it's taking place
- Houston, Texas, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 99 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Houston, Texas, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.